Progress and New Challenges in Combatting the Threat of Antimicrobial Resistance: Perspective From an Infectious Diseases Pharmacist.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. Mitigating Antimicrobial Resistance Through an Ecological One-Health Framework.EcoHealth · 2026
   Review
2. Machine Learning in the ICU: Predicting Mortality in Patients with Carbapenem-Resistant Gram-Negative Bacilli Bloodstream Infections.Journal of intensive care medicine · 2026
   Article
3. The changing epidemiology and long-term outcomes of patients with CRE infections.Antimicrobial stewardship & healthcare epidemiology : ASHE · 2026
   Article
4. Antibacterial Compounds Isolated from Endophytic Fungi Reported from 2021 to 2024.Antibiotics (Basel, Switzerland) · 2025
   Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

1 author.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as